Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib by Nicholas Gravbrot, Srinath Sundararajan

“…Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Findings: From December 14th, 2016, to August 14, 2019, 140 patients enrolled into seven cohorts. The rare melanoma cohorts were closed due to lack of accrual. …”
Get full text

Clinicopathological Analysis and Surgical Outcome of Eyelid Malignancies: A Study of 332 Cases by Syeed Mehbub Ul Kadir, Mukti Rani Mitra, Riffat Rashid, Murtuza Nuruddin, Md. Kamrul Hassan Khan, Golam Haider, Mst. Sayedatun Nessa

“…Pigmentation was associated with malignant melanoma (100%) and BCC (81%). Statistically, a significant difference was found between eyelid malignancies, including location, size, pigmentation, recurrence, and invasiveness. …”
Get full text

Evaluation of the Antioxidant and Cytotoxic Activities on Cancer Cell Line of Extracts of Parasitic Plants Harvested in Tunisia by Imen Ben Attia, Paolo Zucca, Flaminia Cesare Marincola, Mariella Nieddu, Alessandra Piras, Antonella Rosa, Antonio Rescigno, Mohamed Chaieb

“…The cytotoxic effect of the oil from the parasitic plants was also studied on B16F10 melanoma cancer cells. All extracts showed antioxidant activity and differences between extracts obtained using different solvents as well as for different plants have been highlighted. …”
Get full text

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer by Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

“…Among patients receiving PD-L1 inhibitors, NSCLC (94.4%) was the predominant malignancy, whereas for those treated with PD-1 inhibitor, malignant melanoma constituted the most prevalent malignancy (34.5%). …”
Get full text

Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome by Benjamin Chaucer, Abriella Stone, Augustus Demanes, Shawn M. Seibert

“…Nivolumab is one of the chemotherapeutic agents commonly used for treatment of renal cell carcinoma, metastatic melanoma, and metastatic non-small cell lung cancer. …”
Get full text

Cutaneous Human Papillomavirus E7 Type-Specific Effects on Differentiation and Proliferation of Organotypic Skin Cultures by K. Westphal, B. Akgül, A. Storey, I. Nindl

“…Background: A role for cutaneous human β-papillomavirus (HPV) types as co-factors in the development of non-melanoma skin cancer has been postulated. Here we have investigated the effects of E7 expression on keratinocyte differentiation, proliferation and cell-cycle proteins in organotypic skin cultures.…”
Get full text

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation by Chang Liu, Miao Wang, Changli Xu, Bo Li, Juxiang Chen, Jianchun Chen, Zhiwei Wang

“…On this basis, we expounded the clinical application of immune checkpoint inhibitors for bone metastasis of common tumors, including non-small-cell lung cancer, renal cell carcinoma, prostate cancer, melanoma, and breast cancer. Then, the deficiencies and limitations in current researches were summarized. …”
Get full text

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade by Junjie Li, Yuandong Luo, Quanlan Fu, Shuxian Tang, Pingping Zhang, Ian H. Frazer, Xiaosong Liu, Tianfang Wang, Guoying Ni

“…We show that F1/F3 is able to inhibit the growth of melanoma B16 tumour cells both in vitro and in vivo. …”
Get full text

Verification of the Functional Antioxidant Activity and Antimelanogenic Properties of Extracts of Poria cocos Mycelium Fermented with Freeze-Dried Plum Powder by Kyung-Yun Kang, Yun-Ho Hwang, Sung-Ju Lee, Ho-Yeol Jang, Seong-Gyeol Hong, Seul-Ki Mun, Su-Jin Kim, Jong-Jin Kim, Kuyng-Wuk Park, Kyoung-Sun Seo, Seung-Eon Ban, Seong-Woo Jin, Hyuck-Joo Kim, Sung-Tae Yee

“…Here we examine the effects of extracts of Poria cocos mycelium fermented with freeze-dried plum powder (PPE) on the α-melanocyte stimulating hormone (α-MSH)-stimulated melanogenesis in cultured murine B16 melanoma cells (B16 cells), relative to the effects of Prunus extract. …”
Get full text

Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol by Lisa Kuramoto, Larry D Lynd, Amir Khakban, Jacquelyn J Cragg, Anthony Traboulsee, Jiwon Oh, Analisa Jia, Weng Sut Sio, M A De Vera, Jonathan Loree, Roger Tam

“…The outcome of interest will be skin cancer (melanoma and non-melanoma skin cancers). Survival analysis will be used to estimate HRs and corresponding 95% CIs, adjusted for potential confounders.Ethics and dissemination Ethics approval for this study was obtained from the University of British Columbia Clinical Research Ethics Board (H24-03199). …”
Get full text

ANALYSIS OF CELLULAR REACTION TO IFN-γ STIMULATION BY A SOFTWARE PACKAGE GeneExpressionAnalyser by A. V. Saetchnikov, M. M. Yatskou, P. V. Nazarov, L. Vallar, V. V. Apanasovich

“…The efficiency of the developed package is tested on the published experimental data devoted to the time-course research of the changes in the human cell un-der the influence of IFN-γ on melanoma. The developed software has a number of advantages over the existing software: it is free, has a simple and intuitive graphical interface, allows to analyze different types of DNA microarrays, contains a set of methods for complete data analysis and performs effec-tive gene annotation for a selected list of genes.…”
Get full text

RPE Adenocarcinoma as the Presenting Sign of Bronchogenic Carcinoma: Diagnostic Dilemma in the Management of a Case by Namrata Adulkar, Santhi Radhakrishnan, N. Vidhya, Usha Kim

“…Neoplasms of retinal pigment epithelium are rare and must be differentiated from choroidal melanoma. The possibility of a metastatic disease with possible primary sites as lung, breast, or kidney should be ruled out. …”
Get full text

Computer Aided Diagnostic Support System for Skin Cancer: A Review of Techniques and Algorithms by Ammara Masood, Adel Ali Al-Jumaily

“…Image-based computer aided diagnosis systems have significant potential for screening and early detection of malignant melanoma. We review the state of the art in these systems and examine current practices, problems, and prospects of image acquisition, pre-processing, segmentation, feature extraction and selection, and classification of dermoscopic images. …”
Get full text

Interleukin 2-Based Fusion Proteins for the Treatment of Cancer by Alana MacDonald, T.-C. Wu, Chien-Fu Hung

“…The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. …”
Get full text

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer by Joshua Mangerel, MD, Andres Rodriguez-Sein, MD, Daniel Masri, MD

“…Leptomeningeal carcinomatosis is a form of advanced metastatic disease conferring poor prognosis, most commonly associated with melanoma, small cell lung cancer, and breast cancer. …”
Get full text

1,25-Vitamin D-mediated hypercalcaemia in the setting of immune therapy-related sarcoid-like reaction by R K Dharmaputra, N Sheriff, S Ravichandran

“…We presented a case of a 72-year-old male with severe hypercalcaemia of 3.84 mmol/L following the second cycle of immunotherapy with ipilimumab and nivolumab in the setting of metastatic melanoma with known bone metastases. Further investigations demonstrated hilar lymphadenopathy, which was not present in previous imaging, and subsequent hypercalcaemia work-up demonstrated a significantly elevated serum calcitriol level as high as 429 pmol/L. …”
Get full text

The high cancer incidence in young people in Italy: do genetic signatures reveal their environmental causes? by Ruggero Ridolfi

Get full text

Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications by Mario Sznol, Naiyer Rizvi

“…Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development.…”
Get full text

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis by Sehhoon Park, Jaeyun Jung, You Jeong Heo

“…The response rate to anti-PD-(L)1 therapy was substantially higher in GC (71.4% vs 25.8%), GBC (50.0% vs 12.5%), head and neck cancer (50.0% vs 11.1%), and melanoma (71.4% vs 50.7%) among TMB-H patients when compared with low TMB (TMB-L) (<10 mt/Mb) patients with statistical significance. …”
Get full text